Charles Leath
Gynecologic Oncology · Birmingham, ALNPI 1255313193
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (41.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Merck at 57.5% of the total. 2025 is the largest year on record at $48,690, 6.5 times the $7,474 reported in 2019. Among gynecologic oncology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 104 payments — averaging $1422.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$85K
- GSK$20K
- Eisai Inc.$10K
- Seagen Inc.$8K
- AbbVie$7K
- Acrotech Biopharma Inc.$6K
- plus $12K from 11 others
Across 189 payments — averaging $9005.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$466K
- Merck$331K
- Corcept Therapeutics$267K
- Tesaro, Inc.$162K
- Incyte Corporation$137K
- Astrazeneca UK Limited$118K
- plus $220K from 7 others
What the payments were for
- Consulting fees$60,96541%
- Speaking & faculty fees$50,97534%
- Travel & lodging$33,45223%
- Food & beverage$2,5682%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 27 | $85,092 |
| GSK | 13 | $19,582 |
| Eisai Inc. | 16 | $9,691 |
| Seagen Inc. | 7 | $8,247 |
| AbbVie | 9 | $7,227 |
| Acrotech Biopharma Inc. | 7 | $6,055 |
| Clovis Oncology, Inc. | 8 | $4,998 |
| Genmab U.S., Inc. | 1 | $3,200 |
| Pfizer | 2 | $3,075 |
| Immunogen, Inc. | 4 | $271 |
| Caris MPI, Inc. | 1 | $213 |
| Karyopharm Therapeutics Inc. | 2 | $121 |
| Intuitive Surgical | 3 | $101 |
| Aadi Bioscience, Inc. | 1 | $50 |
| AstraZeneca | 1 | $20 |
| Boston Scientific | 1 | $20 |
| Medical Device Business Services, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$147,983 in reported general payments places this provider in the 95th percentile of 27 gynecologic oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 54 | $608 |
| Morphine Sulfate ErMorphine Sulfate | 12 | $349 |
| Gabapentin | 28 | $311 |
| Pregabalin | 20 | $269 |
| Medroxyprogesterone Acetate | 15 | $192 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Birmingham
- Rebecca ArendBirmingham$70K
- Warner HuhBirmingham$59K
- David DooBirmingham$9K
- Michael ToboniBirmingham$8K
- Margaret LiangBirmingham$3K
- Wesley BurkettBirmingham$3K
- Monjri ShahBirmingham$2K
- Kaitlyn DinkinsBirmingham$2K
- Christopher MayerBirmingham$1K
- Teresa BoitanoBirmingham$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.